The final systematic review protocol for Topical Treatment of Psoriasis With Roflumilast and Tapinarof is now available, and PCORI is seeking supplemental evidence and data relevant to the systematic review. Researchers, professional societies, industry associates and other interested parties are invited to submit relevant evidence, including unpublished research and detailed study-specific findings. Submit your input by Sept. 16: pcori.me/46PkLGt